Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 29, 2004. The report details corporate actions regarding share repurchases, treasury holdings, and director interests, rather than presenting a full financial statement for a fiscal period.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data disclosed relates to share transactions:
- Share Repurchase: 1,850,000 Ordinary Shares purchased on March 26, 2004.
- Purchase Price: 1,076.47 pence per share.
- Treasury Holdings: 8,370,000 shares held in treasury following the purchase.
- Shares in Issue: 5,934,544,296 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program authorized at the Annual General Meeting on May 19, 2003. Additionally, the GSK Trust transferred 40,594 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. It notes that the announcement does not constitute an offer to purchase securities. The company has applied for block listings totaling 185,185 Ordinary shares to be issued under various employee share option schemes, which will rank pari passu with existing shares.
Investor Verification Checklist
- Verify the total cost of the 1,850,000 share repurchase against the stated price of 1,076.47 pence.
- Confirm the updated total share count (5,934,544,296) in subsequent filings.
- Review the status of the 185,185 shares applied for listing under employee option schemes.
- Check for any further disclosures regarding the GSK Trust and director interests.